Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus NEXIUM IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM versus NEXIUM IV.
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM vs NEXIUM IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
Proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Esomeprazole is the S-isomer of omeprazole, which is concentrated in the acidic environment of parietal cells and converted to the active sulfenamide form that binds covalently with the proton pump, leading to irreversible inhibition.
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
20-40 mg intravenously once daily; for GERD with erosive esophagitis: 20-40 mg once daily; for Zollinger-Ellison syndrome: 80 mg IV every 12 hours, adjust based on acid output.
None Documented
None Documented
Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation).
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class A, B, or C), half-life may be prolonged up to 2.9-8 hours.
Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal.
Renal (approx. 80% as inactive metabolites), fecal (approx. 20% as metabolites and parent drug). Less than 1% excreted unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor